Diaxonhit Share Price Euronext Paris
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 25Cr 29Cr 24Cr 22Cr 41Cr 2.76TCr 41Cr 285.61Cr 110.62Cr 1.41TCr 108.13Cr 105.79Cr 4.53TCr | P/E 2026 * |
22.2x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 22Cr 25Cr 21Cr 19Cr 36Cr 2.41TCr 36Cr 249.45Cr 97Cr 1.23TCr 94Cr 92Cr 3.96TCr | EV / Sales 2026 * |
1.25x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 13/06/2023 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 10/10/2023 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 01/01/2019 | |
Michel Picot
BRD | Director/Board Member | 73 | 27/06/2019 |
| Director/Board Member | 69 | 15/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | -.--% | - | - | 29Cr | |
| -0.14% | +4.33% | +9.00% | +31.64% | 4.8TCr | |
| -1.69% | +1.48% | +50.57% | +34.53% | 4.45TCr | |
| +2.56% | +7.34% | +366.69% | +608.26% | 4.39TCr | |
| +0.24% | +2.85% | +10.67% | +94.47% | 4.1TCr | |
| -0.62% | -1.11% | +4.65% | +48.91% | 2.99TCr | |
| -0.28% | +1.07% | +24.58% | +155.58% | 1.73TCr | |
| +3.37% | +9.21% | +8.32% | - | 1.53TCr | |
| -0.46% | +1.20% | +26.90% | +42.21% | 1.53TCr | |
| -2.21% | -4.70% | - | - | 1.48TCr | |
| Average | -0.11% | +2.35% | +62.67% | +145.08% | 3TCr | |
| Weighted average by Cap. | +0.11% | +2.86% | +79.67% | +160.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18Cr 20Cr 17Cr 15Cr 28Cr 1.92TCr 29Cr 198.8Cr 77Cr 981.53Cr 75Cr 74Cr 3.15TCr | - |
| Net income | 1.16Cr 1.32Cr 1.1Cr 99.84L 1.87Cr 126.7Cr 1.88Cr 13Cr 5.08Cr 65Cr 4.96Cr 4.86Cr 208.03Cr | - |
| Net Debt | -3.2Cr -3.65Cr -3.02Cr -2.75Cr -5.16Cr -349.52Cr -5.19Cr -36Cr -14Cr -178.56Cr -14Cr -13Cr -573.88Cr | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
